Lab Approach for Basket Trials in Advanced Tumors. Mohamed Salama M.D. Professor of Pathology, University of Utah
|
|
- Prosper Douglas
- 5 years ago
- Views:
Transcription
1 Lab Approach for Basket Trials in Advanced Tumors Mohamed Salama M.D. Professor of Pathology, University of Utah
2 Objectives Discuss how to support basket trials as a pathology department Basket trials require an integrated approach that brings together microscopic work, screening and confirmation lab testing as well coordination with the clinical team
3 Outline Pathology and clinical trials design Basket trials can offer opportunities or challenge STARTRK-2 Trial as a case study Patients response Laboratory approach IHC NGS Digital Expression Profiling (Nano string) Future directions and academic opportunities
4 Clinical Trial Paradigm Basket Trials Umbrella Trials VS
5 Umbrella Trials Histology-specific genotyping study
6 Basket Trials Histology-independent, aberration specific Targeted drug, develop simultaneously across organ- specific tumors, restricted to those expressing target Sample sizes tiny, borrow but do not pool (formalizes Gleevec phenomenon )
7 The Logistics of Implementing Basket Trials To be successful, basket trials require coordination across tumor areas lung, GI, head and neck, hematology, sarcoma/melanoma, gyn, etc. Oncopolitics sets up communication barriers between these groups These trials often require new testing methodologies for example testing heterogeneous fusions across tumor types this takes time and money to implement Pathology is a central player in basket trials
8 STARTRK-2 Trial as an Example Case Study Huntsman Cancer Institute was selected as a site for STARTRK-2 trial ARUP is a pathology service provider for Huntsman, identify fusions of NTRK, ROS1, and ALK across many tumor types
9 STARTRK-2 Trial An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
10 Entrectinib (RXDX-101): A First-in-Class Trk Inhibitor and Potential Best-in-Class ROS1 Inhibitor Most potent, orally available pan-trk inhibitor in clinical development Target TrkA TrkB TrkC ROS1 ALK IC50* (nm) Most potent pan-trk-inhibitor in clinical development with activity against most of the known Trk-resistant mutants 30x more potent against ROS1 than crizotinib; high potency against ALK Designed to cross blood brain barrier (BBB) and to address CNS metastases, a common complication of advanced solid tumors Demonstrates inhibition of its RTK targets and downstream effectors in the PLCγ, MAPK and PI3K/AKT pathways Entrectinib-mediated inhibition of oncogenic fusion proteins results in rapid tumor response in preclinical models and in selected patient populations * Biochemical kinase assay
11 Sum of longest diameter, maximum decrease from baseline (%) Antitumor Activity in ALK and ROS1 Inhibitor-Naïve Patients with NTRK1/2/3, ROS1, or ALK Gene Rearrangements 25 patients treated 30 Data cutoff 07 March patients with extracranial solid tumors, locally assessed Overall Response Rate: 19/24 (79%) NTRK patients: 3/3 (100%) ROS1 patients: 12/14 (86%) PD PR ALK patients: 4/7 (57%) patient with NTRK+ astrocytoma -60 SD by RECIST* 45% by exploratory 3-D volumetric assessment Enhancing Volume (cm 3 ) Non-Enhancing Volume (cm 3 ) entrectinib initiated cm cm CR Jul 2015 Feb 2016 * RECIST criteria not validated in primary brain tumors (FDA-AACR Brain Tumor Endpoints Workshop 2006)
12 Gene Rearrangements Targeted by Entrectinib Are Present in a Large Number of Tumors NTRK1 NTRK2 NTRK3 ROS1 ALK NSCLC (adeno, large cell NE) 1-3% <1% <1% 1-2% 3-7% CRC 1-2% 1% 1-2% 1-2% Salivary gland mammary analog secretory carcinoma [MASC] % Salivary gland NOS 3% Sarcomas (including GIST) 1-9% 2-11% 2-3% 1-5% Astrocytoma 3% Glioblastoma 1-3% 1% Melanoma (Spitz) 16% 17% 10% Cholangiocarcinoma 4% 9% 2% Papillary thyroid carcinoma 4-13% 2-14% 7% Breast secretory carcinoma 92% Breast NOS 2%
13 Clinical response to entrectinib in a 46 year-old male patient with NTRK1-rearranged NSCLC
14 Response of Brain Metastases
15 NTRK1 (TrkA) Rearrangements Across Tumors Signal Peptide/Extracellular Domain CRC, PTC, NSCLC, sarcoma, pediatric glioma, breast, gallbladder, cholangiocarcinoma CRC, Spitzoid melanoma, sarcoma NSCLC, PTC, sacrcoma CRC, PTC Sarcoma, breast cancer NSCLC, GBM NSCLC, PTC NSCLC NSCLC Spitzoid melanoma PTC GBM Astrocytoma/GBM Breast cancer Cholangiocarcinoma PTC GBM GBM PTC Pancreatic cancer PTC NSCLC Uterus carcinoma NSCLC TM Kinase Domain NTRK (wild-type) TPM3-NTRK1 LMNA-NTRK1 SQSTM1-NTRK1 TPR-NTRK1 PEAR1-NTRK1 CD74-NTRK1 IRF2BP2-NTRK1 MPRIP-NTRK1 RFWD2-NTRK1 TP53-NTRK1 TFG-NTRK1 NFASC-NTRK1 BCAN-NTRK1 MDM4-NTRK1 RABGAP1L-NTRK1 PPL-NTRK1 CHTOP-NTRK1 ARHGEF2-NTRK1 TAF-NTRK1 CEL-NTRK1 SSBP2-NTRK1 GRIPAP1-NTRK1 LRRC71-NTRK1 MRPL24-NTRK1
16 STARTRK-2 Clinical Trial Testing Strategy: IHC enrichment followed by NGS Step 1: IHC screening Step 2: Sequencing 1. IHC cocktail to detect expression in NTRK1/2/3, ROS1, ALK a hallmark of gene rearrangement 2. Removes 50-70% of cases from further Dx consideration 1. RNA based Anchored multiplex PCR library preparation 2. Less bias for gene rearrangements
17 Finding the Responders
18 IHC Measures Active Protein Oncogenic gene rearrangements need to produce active chimeric protein (e.g., in frame). This will not be observed with typical methods, such as FISH. Example: Ovarian carcinoma, clear cell Pan-IHC- (ALK IHC-) ALK FISH+ (confirmed)
19 Colorectal Adenocarcinoma Pan-IHC ALK NTRK FISH+ NGS TPM3:NTRK1 ROS1 Trk Lee, et al, Samsung
20 Colorectal Adenocarcinoma ALK expression from gene fusion but also background Trk expression Pan-IHC ALK ALK FISH+ NGS EML4:ALK ROS1 Trk Lee, et al, Samsung
21 Application Across Multiple Tissue Types IHC Step 1: Enrichment Site: n Neg Pos %Pos Prostate % Colon % Thyroid % Lung % Breast % Skin % Ovary % Brain % Stomach/GI % Totals: % Boomer, et al, (2015) AACR IHC IHC IHC NGS Step 2: Fusion Detection Colon (5.5%) Pos Neg Pos 5 31 Neg 0 54 Thyroid (3.5%) Pos Neg Pos 1 6 Neg 0 21 Lung (3%) Pos Neg Pos 2 41 Neg 0 31
22 Multiple Methods NEXT GENERATION SEQUENCING (NGS) 22
23 The Challenge Detecting Fusions in NTRK1/2/3, ROS1 and ALK Genes With such large intronic spaces (and difficult regions within them), fusion detection by DNA NGS can be complicated Lower capacity (fewer samples to multiplex to get appropriate coverage) More complications with difficult introns NTRK1 NTRK2 NTRK3 NTRK2, Intron 14 ~109kb NTRK3, Intron 13 ~93kb Intron Exon ROS1 ALK 23
24 Advantage of RNA for Gene Rearrangements Gets around the intron problem looking for exon/exon junctions 24
25
26 Beadling et al J Mol Diagn 2016, 18:
27 Overview - NGS Assay for Rearrangements SAMPLE FFPE Slides EXTRACTION Total Nucleic Acid Extraction: Agencourt Formapure Kit Microdissection Sequence/ Analyze Sequencing on MiSeq Custom informatics Library Preparation Enzymatics RNA 27
28 Anchored Multiplex PCR (AMP) overview cdna or DNA fragments End repair, d/a-tailing Adapter ligation Partially functional MBC adapter P5 Primer Barcode Universal primer binding site GSP1 Gene Specific Primer 1 (GSP1) GSP2 Nested PCR with GSP2 Sequencing-ready library
29 Archer AMP vs Opposing Primers (Ampliseq/Oncomine) Anchored Multiplex PCR Traditional Opposing Primers AMP library Amplicon library Unique, barcoded ends Indistinguishable amplicons, Lost information *Courtesy: ArcherDx
30 Gene Rearrangements Detected in Association with STARTRK-2 Head & Neck Sarcomas Gastrointestinal - Salivary gland cancer (MASC): NTRK - Sarcoma: ALK, NTRK - CRC: NTRK, ROS1, ALK - Squamous cell: NTRK, ALK - Soft tissue angiosarcoma: ROS1, ALK - CRC (appendiceal): NTRK - Papillary thyroid: NTRK, ROS1, ALK - Infatile fibrosarcoma: NTRK - Cholangiocarcinoma: NTRK Thoracic - Gliosarcoma: NTRK - Gastroesophageal: NTRK, ROS1 - NSCLC (adeno): NTRK, ROS1, ALK - Uterine adenosarcoma: NTRK - Pancreas: NTRK, ALK - NSCLC (squamous): NTRK, ROS1, ALK - Liposarcoma: NTRK - Bile duct: NTRK - Small cell carcinoma: ROS1, ALK - Ewing's sarcoma: ALK - Stomach adenocarcinoma: NTRK CNS - Stromal sarcoma: NTRK Genitourinary - Gliosarcoma: NTRK Breast - Renal cell carcinoma: ALK - Astrocytoma: NTRK - Breast (secretory): NTRK Other - Glioblastoma multiforme: ROS1 - Breast: ROS1, ALK - Melanoma: ROS1 Gynecological Hematological Malignancies - Neuroendocrine: NTRK - Uterine adenosarcoma: NTRK - Anaplastic lymphoma: ALK - Soft tissue myofibroblastic tumor: ROS1 - Ovarian/fallopian epithelial: NTRK, ALK - Pediatric ALL: NTRK - Peripheral nerve sheath tumor: NTRK - Uterine Leiomyosarcoma: ALK - Mutliple myeloma: NTRK Gene rearrangements detected through Ignyta and other collaborative diagnostic partnerships
31 LASTLY - NANOSTRING 31
32 Nanostring Technology Gene 1 Gene 2 Gene 3 Direct measurement of RNA expression (no PCR) Can be used in degraded samples (FFPE)
33 Int. Jnl. Lab. Hem. 2015, 37, Junction Probe
34 5 /3 Positional Imbalanced Probe Gene Expression Design: No partner information EML4-ALK (exon 20)
35 5 /3 Positional Imbalanced Probe Gene Expression Design: Wild-type expression can complicate analysis - Difficult to identify the fusion threshold with a background - Use of fusion specific probes can assist for known partners Exon 1 Exon 43 EZR:ROS1 (exon 34) Lira ME etal. J Mol Diagn. 2014; 16(2):
36 Summary Basket trials provide opportunity for integration of platforms; (IHC, microscopic identification of secretory tumor) and (Nanostring, Illlumina NGS) to work together Pathologists role is essential in basket trials helping oncologists identify patients. Trials like STARTRK-2 present opportunities to advance technology and innovation 36
37 Questions?
RXDX-101 & RXDX-102. Justin Gainor, MD February 20 th, 2014
RXDX-101 & RXDX-102 Justin Gainor, MD February 20 th, 2014 Background Chromosomal fusions are important oncogenic drivers in NSCLC - ALK Rearrangements (4-6%) - ROS1 Rearrangements (1-2%) - RET Rearrangements
More informationPLX7486 Background Information October Candidate for CRUK Combinations Alliance
PLX7486 Background Information October 2015 Candidate for CRUK Combinations Alliance 1 Oct 2015 Plexxikon s Development Pipeline Compound Target Cancer Indication Stage of Development Pre- IND Ph1 Ph2
More informationClinical response to entrectinib in a patient with NTRK1-rearranged non-small cell lung cancer (NSCLC)
Clinical response to entrectinib in a patient with NTRK1-rearranged non-small cell lung cancer (NSCLC) Anna F. Farago, Manish Patel, Todd M. Bauer, Stephen V. Liu, Alexander Drilon, Jennifer Wheler, Sai-Hong
More informationFusion Analysis of Solid Tumors Reveals Novel Rearrangements in Breast Carcinomas
Fusion Analysis of Solid Tumors Reveals Novel Rearrangements in Breast Carcinomas Igor Astsaturov Philip Ellis Jeff Swensen Zoran Gatalica David Arguello Sandeep Reddy Wafik El-Deiry Disclaimers Dr. Igor
More informationDevelopment of LOXO-101 in Adult and Pediatric Patients With Cancer
Development of LOXO-101 in Adult and Pediatric Patients With Cancer Michael Craig Cox, PharmD, MHSc, BCOP Director, Clinical Development & Medical Affairs Loxo Oncology, Inc. 1 Thematic Convergence Underscores
More informationEfficacy of larotrectinib in adolescents and young adults with TRK fusion cancer
Efficacy of larotrectinib in adolescents and young adults with TRK fusion cancer Soledad Gallego, 1 Valentina Boni, 2 Ulrik Lassen, 3 Anna Farago, 4 Wafik El-Deiry, 5 David Hong, 6 Blanca López-Ibor, 2
More informationActivity of larotrectinib in patients with TRK fusion GI malignancies
Activity of larotrectinib in patients with TRK fusion GI malignancies Michael Nathenson 1, George Demetri 1, Ulrik Lassen 2, David Hong 3, Valentina Boni 4, John Deeken 5, Afsin Dowlati 6, Michael Cox
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationA pediatric phase 1 study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family: an updated analysis
A pediatric phase 1 study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family: an updated analysis Turpin B, 1 Albert CM, 2 Mascarenhas L, 3 Federman N, 4 Nagasubramanian
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationQuality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024
Quality in Control ROS1 Analyte Control Product Codes: HCL022, HCL023 and HCL024 Contents What is ROS1? 2 The Role of ROS1 in Cancer 3 ROS1 Assessment 3 ROS1 Analyte Control Product Details 4 ROS1 Analyte
More informationValida5on of a Microsatellite Instability Assay by NGS
Valida5on of a Microsatellite Instability Assay by NGS Mark R. Miglarese, Ph.D. VP R&D 1 Caris Life Sciences 230,000+ tests performed in 2016 Headquarters: Irving, Texas Laboratory: Phoenix, Arizona 66,000
More informationCharacterization of TRK fusions and therapeutic response to TRK inhibition in hematologic malignancies
Characterization of TRK fusions and therapeutic response to TRK inhibition in hematologic malignancies Taylor J, 1 Yoshimi A 1, Marcelus C 1, Pavlick D 2, Benayed R 1, Cocco E 1, Durham BH 1, Hechtman
More informationRare Cancers. Andrew J. Wagner, MD, PhD Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Sarcoma Patient Symposium October 15, 2017
Rare Cancers Andrew J. Wagner, MD, PhD Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Sarcoma Patient Symposium October 15, 2017 Why should we care about Rare Cancers? Raise your hand
More informationCatalyzing Precision Medicine with Integrated Rx/Dx in Oncology. Jefferies Healthcare Conference June 8 th, 2016
Catalyzing Precision Medicine with Integrated Rx/Dx in Oncology Jefferies Healthcare Conference June 8 th, 2016 Safe Harbor Statement This document contains forward-looking statements, as that term is
More informationEl contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD
El contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD Laboratorio de Dianas Terapéuticas Hospital Universitario HM Sanchinarro Madrid, Spain Contents Background PD-L1 expression
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationThe use of larotrectinib in the management of locally advanced pediatric NTRK-fusion sarcoma
The use of larotrectinib in the management of locally advanced pediatric NTRK-fusion sarcoma DuBois SG, 1 Laetsch TW, 2 Federman N, 3 Albert CM, 4 Turpin B, 5 Nagasubramanian R, 6 Reynolds M, 7 Cruickshank
More informationRob Ross, MD. Infinity Pharmaceuticals March 9 th, 2011
Heat Shock Protein 90 (Hsp90) Inhibition as a Potential Novel Approach to the Treatment of Patients with ALK Mutated Non-small Cell Lung Cancer (NSCLC) Rob Ross, MD Infinity Pharmaceuticals March 9 th,
More informationCODING TUMOUR MORPHOLOGY. Otto Visser
CODING TUMOUR MORPHOLOGY Otto Visser INTRODUCTION The morphology describes the tissue of the tumour closest to normal tissue Well differentiated tumours are closest to normal Undifferentiated tumours show
More informationExpanding Therapeutic Options for Cancer Patients with Comprehensive Profiling Alexander Drilon MD
Expanding Therapeutic Options for Cancer Patients with Comprehensive Profiling Alexander Drilon MD Clinical Director, Early Drug Development Service Memorial Sloan Kettering Cancer Center COI Disclosure
More informationApproval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology
Approval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology Steven Lemery, MD, MHS Associate Director, DOP2 Traditional development paradigm Based on tumor
More informationPRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019
MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationLarotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach
Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach Ulrik Lassen, 1 Catherine M. Albert, 2 Shivaani Kummar, 3
More informationList of Available TMAs in the PRN
TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationDiscovery of Essential Growth Drivers in Cancer Brings Magical Drugs to Patients
Discovery of Essential Growth Drivers in Cancer Brings Magical Drugs to Patients Hiroyuki Mano, MD, PhD Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Japan What
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationMET skipping mutation, EGFR
New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM
More informationACCME/Disclosures ALK FUSION-POSITIVE MESENCHYMAL TUMORS. Tumor types with ALK rearrangements. Anaplastic Lymphoma Kinase. Jason L.
Companion Meeting of the International Society of Bone and Soft Tissue Pathology The Evolving Concept of Mesenchymal Tumors ALK FUSION-POSITIVE MESENCHYMAL TUMORS Jason L. Hornick, MD, PhD March 13, 2016
More informationDurable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
Brief Report Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer Anna F. Farago, MD, PhD,* Long P. Le, MD, PhD, Zongli Zheng, PhD, Alona Muzikansky, MA,* Alexander Drilon,
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationSupplementary Online Content
Supplementary Online Content Chacón MR, Enrico DH, Burton J, Waisberg FD, Videla VM. Incidence of placebo adverse events in randomized clinical trials of targeted and immunotherapy cancer drugs in the
More informationThe clinically challenging entity of liver metastasis from tumors of unknown primary
The clinically challenging entity of liver metastasis from tumors of unknown primary Xuchen Zhang, MD, PhD Associate Professor of Pathology Department of Pathology Yale University School of Medicine Liver
More informationCurrent and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian
Current and future applications of Molecular Pathology Kathy Walsh Clinical Scientist NHS Lothian Molecular Pathology in Solid tumours Cancer type Genes tested Purpose Associated treatments Non small cell
More informationImmunohistochemical classification of lung carcinomas and mesotheliomas. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark
Immunohistochemical classification of lung carcinomas and mesotheliomas Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Endobronchial ultrasound guided transbronchial needle biopsy
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationMaking the TRK to Precision Medicine in Cancer The Promise of Targeting TRK Fusions in Lung, Breast, GI, and Other Tumors
Making the TRK to Precision Medicine in Cancer The Promise of Targeting TRK Fusions in Lung, Breast, GI, and Other Tumors Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed,
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More information2018 ICD-O-3 Updates in Table Format with Annotation for Reference
Status Histology Description (this may be preferred term or a synonym) Report Comments New term 8010 3 Urachal carcinoma (C65.9, C66.9, C67._, C68._) New term 8013 3 Combined large cell neuroendocrine
More informationDisclosure of Relevant Financial Relationships NON-SMALL CELL LUNG CANCER: 70% PRESENT IN ADVANCED STAGE
MORPHOLOGY AND MOLECULAR TESTING IN NON-SMALL CELL OF LUNG NEW FRONTIEIRS IN CYTOPATHOLOGY PRACTICE American Society for Cytopathology San Antonio, Texas Sunday March 5, 2017 Disclosure of Relevant Financial
More informationAdaptive Design of Affordable Clinical Trials Using Master Protocols in the Era of Precision Medicine
Adaptive Design of Affordable Clinical Trials Using Master Protocols in the Era of Precision Medicine Tze Leung Lai Dept. of Statistics, Biomedical Data Science, Computational & Mathematical Engineering;
More informationMolecular Pathology and Lung Cancer. A. John Iafrate MD-PhD Department of Pathology Massachusetts General Hospital Boston, MA
Molecular Pathology and Lung Cancer A. John Iafrate MD-PhD Department of Pathology Massachusetts General Hospital Boston, MA aiafrate@partners.org Disclosures Preliminary patent application NGS AMP Fusion
More informationOncology 101. Cancer Basics
Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases
More informationTumor Agnostic Therapies and Clinical Trial Design
Disclosures Tumor Agnostic Therapies and Clinical Trial Design Current employment: Xcenda Megan Pollack, PharmD, BCOP, BCPS Xcenda Assistant Director, Oncology Medical Communications Objectives Recognize
More informationPersonalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader
Personalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader Agenda PHC Approach Provides Better Patient Outcome FMI offers Comprehensive Genomic Profiling,
More informationFACULTY MEMBERSHIP APPLICATION Tulane Cancer Center
FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center 1430 Tulane Ave., Box SL-68, New Orleans, LA 70112-2699 J. Bennett Johnston Building, Mezzanine (Floor 1A), Suite A102 (504) 988-6060, fax (504) 988-6077,
More informationNGS Gateway Lab Services
TM NGS Gateway Lab Services Accelerating Precision Medicine Design a Complete Genomic Testing Portfolio with Turnkey Assays About NGS Gateway Lab Services TM Designed to provide a gateway to your own in-house
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationBihong Zhao, M.D, Ph.D Department of Pathology
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
More informationOut-Patient Billing CPT Codes
Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationEffective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific
Effective January 1, 2018 codes, behaviors and terms are site specific /N 8551/3 Acinar adenocarcinoma (C34. _) Lung primaries diagnosed prior to 1/1/2018 use code 8550/3 For prostate (all years) see 8140/3
More informationEffective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific
Effective January 1, 2018 codes, behaviors and terms are site specific Status /N 8010/3 Urachal carcinoma (C65.9, C66.9, C67. _, C68._) 8013/3 Combined large cell neuroendocrine carcinoma (C34. _, C37.9)
More informationMolecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.
Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine
More informationDATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #
DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #2006-01 CATEGORY: CLARIFICATION SUBJECT: RESCINDMENT - DSQC MEMORANDUM 2002-08 Coding Complex Morphologic Diagnoses (revised 8/02) EFFECTIVE: For Cases
More informationACR TXIT TM EXAM OUTLINE
ACR TXIT TM EXAM OUTLINE Major Domain Sub-Domain 1 Statistics 1.1 Study design 1.2 Definitions of statistical terms 1.3 General interpretation & analysis 1.4 Survival curves 1.5 Specificity/sensitivity
More informationQIAGEN Complete Solutions for Liquid Biopsy Molecular Testing
QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing Christopher Swagell, PhD Market Development Manager, Advanced Molecular Pathology QIAGEN 1 Agenda QIAGEN Solid Tumor Testing and Liquid Biopsy
More informationSupplementary Figure 1: Tissue of Origin analysis on 152 cell lines. (a) Heatmap representation of the 30 Tissue scores for the 152 cell lines.
Supplementary Figure 1: Tissue of Origin analysis on 152 cell lines. (a) Heatmap representation of the 30 Tissue scores for the 152 cell lines. The scores summarize the global expression of the tissue
More informationOutcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.
More informationImmunohistochemical classification of the unknown primary tumour (UPT) Part I. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark
Immunohistochemical classification of the unknown primary tumour (UPT) Part I Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Tumours of unknown origin: Histology Brain tumour - biopsy
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationMolecular Diagnostics of Head and Neck Tumors Justin A. Bishop, M.D. Associate Professor of Pathology The Johns Hopkins University Baltimore, Maryland
Molecular Diagnostics of Head and Neck Tumors Justin A. Bishop, M.D. Associate Professor of Pathology The Johns Hopkins University Baltimore, Maryland Two Main Topics Molecular insights in salivary gland
More informationNTRK gene fusions as novel targets of cancer therapy across multiple tumour types
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types Review Alessio Amatu, 1 Andrea Sartore-Bianchi, 1 Salvatore Siena 1,2 To cite: Amatu A, Sartore- Bianchi A, Siena S. NTRK
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationIdentification of Novel Variant of EML4-ALK Fusion Gene in NSCLC: Potential Benefits of the RT-PCR Method
International journal of Biomedical science ORIGINAL ARTICLE Identification of Novel Variant of EML4-ALK Fusion Gene in NSCLC: Potential Benefits of the RT-PCR Method Martin K. H. Maus 1, 2, Craig Stephens
More informationOther Driver Mutations: cmet, B-RAF, RET, NTRK
Other Driver Mutations: cmet, B-RAF, RET, NTRK Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology and Medical Director, Memorial Cancer Institute Clinical Professor of Medicine Herbert Wertheim College
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles 30+ Multimethod Assays for Hematologic Diseases and Solid Tumors Molecular FISH Anatomic Pathology The next generation of diagnostic, prognostic, and therapeutic assessment What
More informationPathology Mystery and Surprise
Pathology Mystery and Surprise Tim Smith, MD Director Anatomic Pathology Medical University of South Carolina Disclosures No conflicts to declare Some problem cases Kidney tumor Scalp tumor Bladder tumor
More informationCorporate Medical Policy
Corporate Medical Policy Microarray-based Gene Expression Testing for Cancers of Unknown File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_testing_for_cancers_of_unknown_primary
More informationTumor Markers & Cytopathology
Tumor Markers & Cytopathology Objectives: After learning, student should be able to 1. Describe the basic concepts of tumor markers and Asst. Prof. Prasit Suwannalert, Ph.D. (Email: prasit.suw@mahidol.ac.th)
More informationPredictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities
Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran
More informationMET Inhibitor. Merestinib, LY Drug Discovery Platform: Cancer Cell Signaling. Derived from Christensen JG, et al 1 ; Eder JP, et al.
MET Inhibitor Merestinib, LY2801653 Derived from Christensen JG, et al 1 ; Eder JP, et al. 2 Drug Discovery Platform: Cancer Cell Signaling A Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib
More informationEvening Specialty Conference: Cytopathology
: Cytopathology N. Paul Ohori, M.D. University of Pittsburgh Medical Center Disclosure of Relevant Financial Relationships Disclosure of Relevant Financial Relationships USCAP requires that all planners
More informationTRK Inhibition: A New Tumor-Agnostic Treatment Strategy
Targeted Oncology (2018) 13:545 556 https://doi.org/10.1007/s11523-018-0590-1 REVIEW ARTICLE TRK Inhibition: A New Tumor-Agnostic Treatment Strategy Shivaani Kummar 1 & Ulrik N. Lassen 2 Published online:
More informationAnnual Report. Cape Cod Hospital and Falmouth Hospital Regional Cancer Network Expert physicians. Quality hospitals. Superior care.
Annual Report Cape Cod Hospital and Falmouth Hospital Regional Cancer Network 2013 Expert physicians. Quality hospitals. Superior care. Cape Cod Hospital s Davenport- Mugar Hematology/Oncology Center and
More information2015 EUROPEAN CANCER CONGRESS
2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th
More informationXalkori. Xalkori (crizotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.12 Subject: Xalkori Page: 1 of 6 Last Review Date: June 22, 2017 Xalkori Description Xalkori (crizotinib)
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More information5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff
5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff National molecular screening of patients with lung cancer for a national trial of multiple novel agents. 2000 NSCLC patients/year (late
More informationAn Interactive Guide to ALK+ Lymphoma. Our understanding of lung cancer has changed From one disease to many subtypes LCD
An Interactive Guide to ALK+ Anaplastic Lymphoma Kinase Non-Small Cell Lung (NSCLC) Our understanding of lung cancer has changed From one disease to many subtypes Click to get started Learning about Lung
More informationEvolution of Early Phase Trials: Clinical Trial Design in the Modern Era
Evolution of Early Phase Trials: Clinical Trial Design in the Modern Era Shivaani Kummar, MD, FACP Professor of Medicine (Oncology) Director, Phase I Clinical Research Program Co-Director, Translational
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationThe Cancer Genome Atlas
The Cancer Genome Atlas July 14, 2011 Kenna M. Shaw, Ph.D. Deputy Director The Cancer Genome Atlas Program TCGA: Core Objectives Launched in 2006 as a pilot and expanded in 2009, the goals of TCGA are
More informationSUCCESSFUL IMPLEMENTATION OF A NOVEL TRIAL MODEL THE SIGNATURE PROGRAM
SUCCESSFUL IMPLEMENTATION OF A NOVEL TRIAL MODEL THE SIGNATURE PROGRAM Julio A. Peguero, 1 James A. Knost, 2 Todd M. Bauer, 3 Matthew Taylor, Fadi S. Braiteh, 5 Joseph P. Eder, 6 Howard Safran, 7 Bert
More informationDiagnostic IHC in lung and pleura pathology
Diagnostic IHC in lung and pleura pathology Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark WHO 2004 and Web Malignant mesothelioma Epithelioid
More informationDrug Discovery Platform: Cancer Cell Signaling. MET Inhibitor. Merestinib, LY Christensen JG, et al1; Eder JP, et al 2
MET Inhibitor Drug Discovery Platform: Cancer Cell Signaling Christensen JG, et al1; Eder JP, et al 2 A Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus and Gemcitabine
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationBasket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
Chen and Chi Journal of Hematology & Oncology (2018) 11:78 https://doi.org/10.1186/s13045-018-0622-4 RESEARCH HIGHLIGHT Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
More informationALK positive Lung Cancer. Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan
ALK positive Lung Cancer Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan Objectives What is ALK translocation? What drugs are used in what sequence? How many times
More informationBLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations
BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations Erica Evans Ph.D. New Drugs on the Horizon 2017 AACR Annual Meeting April 2, 2017 Disclosures
More informationExploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser
Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser Melissa S. Cline 1*, Brian Craft 1, Teresa Swatloski 1, Mary Goldman 1, Singer Ma 1, David Haussler 1, Jingchun Zhu 1 1 Center for Biomolecular
More information2 Berkeley Street, Suite 403, Toronto, Ontario M5A 2W3 Visit us at: Tel: Fax:
E-Path A.I. Engine Knowledge Base Enhancements Version 1.0.0.29 April 1, 2018 The major enhancements in the E-Path Knowledge Base from versions 1.0.0.28 through 1.0.0.29 are as follows: 1. Addition/modification
More informationDisclosures. Molecular Cytopathology. Update on Molecular Testing of Cytology Specimens: Beyond the Cell Block. Molecular Cytopathology Solid Tumor
Update on Molecular Testing of Cytology Specimens: Beyond the Cell Block Disclosures None relevant to this talks Dara L. Aisner, M.D., Ph.D. Assistant Professor Co-Director, Colorado Molecular Correlates
More informationLiquid biopsy in lung cancer: The EGFR paradigm
Liquid biopsy in lung cancer: The EGFR paradigm Lynette M. Sholl, M.D. Brigham and Women s Hospital Dana Farber Cancer Institute Department of Pathology Boston, MA Disclosure of Relevant Financial Relationships
More informationMEDICAL PRIOR AUTHORIZATION
MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More information